Navitas Life Sciences

Highly Efficient Safety and Efficacy Evaluation of COVID-19 Therapies in Moderate to Severe Patients

Our client, a multinational mid-sized pharma company needed assistance in running a clinical trial to evaluate the safety and efficacy of an adjunctive therapy in the acute treatment of moderate to severe COVID-19 patients.

Read our latest case study and learn how we are driving operational approaches to evaluate the safety and efficacy of their therapies in moderate to severe COVID-19 patients. From being awarded the studies to date we have:

  • Quickly activated sites within 20 days
  • Achieved FPI within 30 days of study award
  • Recruited Patients ahead of time
  • Comprehensive trial oversight through our in-house analytics platform

Please complete the form to download our case study.

Please complete form to download PDF
First Name
Last Name
Business Email
Job Title
By submitting this form, I agree to receive email communications from Navitas Life Sciences. Privacy Policy | EU-US & Swiss-US Privacy Shield Policy

© 2020 Navitas Life Sciences | Privacy Policy